KR100408138B1 - 아릴 융합된 아자폴리사이클릭 화합물 - Google Patents
아릴 융합된 아자폴리사이클릭 화합물 Download PDFInfo
- Publication number
- KR100408138B1 KR100408138B1 KR10-2000-7007379A KR20007007379A KR100408138B1 KR 100408138 B1 KR100408138 B1 KR 100408138B1 KR 20007007379 A KR20007007379 A KR 20007007379A KR 100408138 B1 KR100408138 B1 KR 100408138B1
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- formula
- mmol
- dodeca
- tricyclo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/24—Camphidines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/08—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims (14)
- 하기 화학식 I의 화합물 또는 그의 약학적으로 허용가능한 염:화학식 I상기 식에서,R1은 수소, (C1-C6)알킬, 비공액 (C3-C6)알케닐, XC(=O)R13, 벤질 또는 -CH2CH2-O-(C1-C4)알킬이고;R2및 R3은 독립적으로 수소, (C2-C6)알케닐, (C2-C6)알키닐, 히드록시, 니트로, 아미노, 할로, 시아노, -SOq(C1-C6)알킬, (C1-C6)알킬아미노-, [(C1-C6)알킬]2아미노-, -CO2R4, -CONR5R6, -SO2NR7R8, -C(=O)R13, -XC(=O)R13, 아릴-(C0-C3)알킬-, 아릴-(C0-C3)알킬-O-, 헤테로아릴-(C0-C3)알킬-, 헤테로아릴-(C0-C3)알킬-O-, X2(C0-C6)알킬- 및 X2(C1-C6)알콕시-(C0-C6)알킬-로 구성된 군에서 선택되고, 이때q는 0, 1 또는 2이고;아릴은 페닐 및 나프틸로 구성된 군에서 선택되고;헤테로아릴은 산소, 질소 및 황으로 구성된 군에서 선택된 1 내지 4개의 헤테로원자를 포함하는 5원 내지 7원의 방향족 고리로 구성된 군에서 선택되고;X2는 존재하지 않거나, (C1-C6)알킬아미노- 또는 [(C1-C6)알킬]2아미노-이며;상기 X2(C0-C6)알킬- 또는 X2(C1-C6)알콕시-(C0-C6)알킬- 중 (C0-C6)알킬- 또는 (C1-C6)알콕시-(C0-C6)알킬- 잔기는 1개 이상의 탄소 원자를 포함하고, X2(C0-C6)알킬- 또는 (C1-C6)알콕시-(C0-C6)알킬- 잔기중 탄소 원자 1 내지 3개는 산소, 질소 또는 황 원자에 의해 임의로 치환될 수 있으나, 단 상기 헤테로원자중 임의의 2개는 2개 이상의 탄소 원자에 의해 분리되어야 하며, (C0-C6)알킬- 또는 (C1-C6)알콕시-(C0-C6)알킬-중 임의의 알킬 잔기는 2 내지 7개의 불소 원자에 의해 임의로 치환될 수 있고;상기 아릴-(C0-C3)알킬- 및 헤테로아릴-(C0-C3)알킬-의 각 알킬 잔기의 탄소 원자중 1개는 산소, 질소 또는 황 원자에 의해 임의로 치환될 수 있고;상기의 각 아릴 및 헤테로아릴 기는 1 내지 7개의 불소 원자로 임의로 치환된 (C1-C6)알킬, 2 내지 7개의 불소 원자로 임의로 치환된 (C1-C6)알콕시, 할로, (C2-C6)알케닐, (C2-C6)알키닐, 히드록시, 니트로, 시아노, 아미노, (C1-C6)알킬아미노-, [(C1-C6)알킬]2아미노-, -CO2R4, -CONR5R6, -SO2NR7R8, -C(=O)R13및 -XC(=O)R13으로 구성된 군에서 독립적으로 선택된 1개 이상의 치환기, 바람직하게는 0 내지 2개의 치환기에 의해 임의로 치환될 수 있거나, 또는R2및 R3은 이들이 결합되어 있는 탄소 원자와 함께, 포화되거나 불포화될 수 있는 4원 내지 7원의 모노사이클릭 또는 10원 내지 14원의 비사이클릭 탄소환 고리를 형성하고, 이때 상기 모노사이클릭 고리의 융합되지 않은 탄소 원자중 1 내지 3개, 및 화학식 I에 나타낸 벤조 고리의 일부가 아닌 상기 비사이클릭 고리의 탄소 원자중 1 내지 5개는 독립적으로 질소, 산소 또는 황에 의해 임의로 치환될 수 있으며, 상기 모노사이클릭 및 비사이클릭 고리는 독립적으로 1 내지 7개의 불소 원자에 의해 임의로 치환된 (C1-C6)알킬, 1 내지 7개의 불소 원자에 의해 임의로 치환된 (C1-C6)알콕시, 니트로, 시아노, 할로, (C2-C6)알케닐, (C2-C6)알키닐, 히드록시, 아미노, (C1-C6)알킬아미노, [(C1-C6)알킬]2아미노, -CO2R4, -CONR5R6, -SO2NR7R8, -C(=O)R13및 -XC(=O)R13으로 구성된 군에서 선택된 1개 이상의 치환기에 의해, 바람직하게는 모노사이클릭 고리에서는 0 내지 2개의 치환기에 의해 그리고 비사이클릭 고리에서는 0 내지 3개의 치환기에 의해 임의로 치환될 수 있고;R4, R5, R6, R7, R8및 R13은 수소 및 (C1-C6)알킬로 구성된 군에서 독립적으로 선택되거나, 또는R5및 R6또는 R7및 R8은 이들이 결합된 질소 원자와 함께, 피롤리딘, 피페리딘, 모르폴린, 아제티딘, 피페라진, N-(C1-C6)알킬피페라진 또는 티오모르폴린 고리, 또는 고리의 황 원자가 설폭사이드 또는 설폰으로 치환된 티오모르폴린 고리를 형성하고;각각의 X는 독립적으로 (C1-C6)알킬렌이나; 단,(a) R1, R2및 R3중 하나 이상은 수소가 아니어야 하고,(b) R2및 R3이 둘다 수소인 경우, R1은 수소, (C1-C6)알킬 또는 비공액 (C3-C6)알케닐일 수 없다.
- 제 1 항에 있어서,R2및 R3이 화학식 I의 벤조 고리와 함께 하기 화학식 XXVI, XXVII, XXVIII, XXIX 및 XXX로 구성된 군에서 선택된 비사이클릭 고리 시스템을 형성하는 화합물:화학식 XXVI화학식 XXVII화학식 XXVIII화학식 XXIX화학식 XXX상기 식들에서,R10및 R17은 독립적으로 (C0-C6)알킬-, (C1-C6)알콕시-(C0-C6)알킬-, 니트로, 시아노, 할로, 아미노, (C1-C6)알킬아미노-, [(C1-C6)알킬]2아미노-, -CO2R4, -CONR5R6, -SO2NR7R8, -C(=O)R13, -XC(=O)R13, 페닐 및 모노사이클릭 헤테로아릴로 구성된 군에서 선택되고, 이때상기 (C0-C6)알킬- 및 (C1-C6)알콕시-(C0-C6)알킬-에서 탄소 원자의 총 수는 6 이하이고, 임의의 알킬 잔기는 1 내지 7개의 불소 원자에 의해 임의로 치환될 수 있으며;헤테로아릴은 산소, 질소 및 황으로 구성된 군에서 선택된 1 내지 4개의 헤테로원자를 포함하는 5원 내지 7원 방향족 고리로 구성된 군에서 선택되고;R4, R5, R6, R7, R8및 R13은 각각 제 1 항에서 정의된 바와 같다.
- 제 1 항에 있어서,R2및 R3이 화학식 I의 벤조 고리와 함께 비사이클릭 또는 트리사이클릭 고리 시스템을 형성하지 않는 화합물.
- 제 1 항에 있어서,R2및 R3중 하나 또는 둘다가 -C(=O)R13이고, 이때 R13이 (C1-C6)알킬인 화합물.
- 제 1 항에 있어서,R2및 R3중 하나가 -COR13이고, 이때 R13이 1 내지 7개의 불소 원자로 임의로 치환된 (C1-C6)알킬 또는 (C1-C3)알킬인 화합물.
- 제 1 항에 있어서,R2및 R3중 하나가 CF3, 플루오로, 시아노 또는 C2F5인 화합물.
- 삭제
- 삭제
- 삭제
- 삭제
- 하기 화학식 I-1의 화합물:화학식 I-1상기 식에서,P는 수소, 메틸, COOR16, -C(=O)NR5R6, -C(=O)H, -C(=O)(C1-C6)알킬, 벤질, t-부톡시카보닐(t-Boc) 또는 트리플루오로아세틸이고, 이때R16은 (C1-C6)알킬, 알릴 또는 2,2,2-트리클로로에틸이며;R5및 R6은 각각 제 1 항에서 정의된 바와 같고;상기 -C(=O)(C1-C6)알킬에서 알킬 잔기는 1 내지 3개의 할로 원자, 바람직하게는 1 내지 3개의 플루오로 또는 클로로 원자로 임의로 치환될 수 있고;R14및 R15는 수소, 1 내지 7개의 불소 원자에 의해 임의로 치환된 (C1-C6)알킬, -C(=O)(C1-C6)알킬, 시아노, 히드록시, 니트로, 아미노, -O(C1-C6)알킬 및 할로로 구성된 군에서 독립적으로 선택되나, 단,P가 수소, (C1-C6)알킬 또는 비공액 (C3-C6)알케닐인 경우, R14및 R15는 둘다 수소일 수 없다.
- 삭제
- 삭제
- 하기 화학식 I-3의 화합물:화학식 I-3상기 식에서,R2및 R3은 각각 제 1 항에서 정의된 바와 같고;P'는 COOR16, -C(=O)NR5R6, -C(=O)H, -C(=O)(C1-C6)알킬, 벤질 또는 t-부톡시카보닐(t-Boc)이고, 이때R16은 알릴, 2,2,2-트리클로로에틸 또는 (C1-C6)알킬이며;R5및 R6은 각각 제 1 항에 정의된 바와 같고;상기 -C(=O)(C1-C6)알킬에서 알킬 잔기는 1 내지 3개의 할로 원자, 바람직하게는 1 내지 3개의 플루오로 또는 클로로 원자로 임의로 치환될 수 있다.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7024597P | 1997-12-31 | 1997-12-31 | |
US60/070,245 | 1997-12-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20010033823A KR20010033823A (ko) | 2001-04-25 |
KR100408138B1 true KR100408138B1 (ko) | 2003-12-01 |
Family
ID=22094096
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2000-7007379A KR100408138B1 (ko) | 1997-12-31 | 1998-11-13 | 아릴 융합된 아자폴리사이클릭 화합물 |
Country Status (52)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101724301B1 (ko) | 2016-11-22 | 2017-04-10 | 주식회사 한서켐 | 바레니클린 살리실산염의 i형 결정 및 그 제조방법 |
Families Citing this family (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1324013C (zh) * | 1997-12-31 | 2007-07-04 | 辉瑞产品公司 | 芳基稠合氮杂多环化合物 |
US6605610B1 (en) * | 1997-12-31 | 2003-08-12 | Pfizer Inc | Aryl fused azapolycyclic compounds |
BR0012793A (pt) | 1999-07-28 | 2002-04-30 | Univ Leland Stanford Junior | Métodos para indução de angiogênese pela administração de nicotina ou outro agonista de receptor de nicotina |
US8188043B2 (en) | 1999-07-28 | 2012-05-29 | The Board Of Trustees Of The Leland Stanford Jr. University | Nicotine in therapeutic angiogenesis and vasculogenesis |
IL137937A0 (en) * | 1999-08-27 | 2001-10-31 | Pfizer Prod Inc | A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
US20020010192A1 (en) * | 2000-06-02 | 2002-01-24 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
US20020016334A1 (en) * | 2000-07-31 | 2002-02-07 | Coe Jotham Wadsworth | Pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (ADHD) |
HUP0303811A3 (en) * | 2001-04-20 | 2008-05-28 | Pfizer Prod Inc | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds |
DE60205742T2 (de) * | 2001-05-14 | 2006-05-11 | Pfizer Products Inc., Groton | Tartratsalze von 5,8,14-Triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen |
CZ20032917A3 (cs) | 2001-05-14 | 2004-07-14 | Pfizer Products Inc. | Citrátová sůl 5,8,14-triazatetracyklo(10,3,1,0 na druhou, na jedenáctou, 0 na čtvrtou, na devátou)-hexadeka-2(11),3,5,7,9-pentaenu |
ES2258652T3 (es) * | 2001-11-29 | 2006-09-01 | Pfizer Products Inc. | Sales de succinato de 5,8,14-triazatetraciclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de los mismos. |
BR0214578A (pt) | 2001-11-30 | 2004-11-03 | Pfizer Prod Inc | Compostos azopolicìclicos fundidos com arila |
DE60218885T2 (de) * | 2001-11-30 | 2008-01-17 | Pfizer Products Inc., Groton | Orale pharmazeutische Arzneiformen bzw. Dosierungsformen von 5,8,14-Triazatetra-cyclo-(10.3.1.0 (2,11).0(4,9)-hexadeca-2(11),3,5,7,9-pentaen mit kontrollierter Freisetzung |
US7303871B2 (en) * | 2002-02-14 | 2007-12-04 | The Board Of Trustees Of The Leland Stanford Junior University | Enzyme treatment of foodstuffs for Celiac Sprue |
US7320788B2 (en) * | 2002-02-14 | 2008-01-22 | The Board Of Trustees Of The Leland Stanford Junior University | Enzyme treatment of foodstuffs for Celiac Sprue |
US8143210B2 (en) * | 2002-02-14 | 2012-03-27 | The Board Of Trustees Of The Leland Stanford Junior University | Enzyme treatment of foodstuffs for celiac sprue |
US7265093B2 (en) * | 2002-05-14 | 2007-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Drug therapy for Celiac Sprue |
WO2003096979A2 (en) * | 2002-05-14 | 2003-11-27 | The Board Of Trustees Of The Leland Stanford Junior University | Drug therapy for celiac sprue |
US7462688B2 (en) * | 2002-05-14 | 2008-12-09 | The Board Of Trustees Of The Leland Stanford Junior University | Peptides for diagnostic and therapeutic methods for celiac sprue |
US7202216B2 (en) * | 2002-05-14 | 2007-04-10 | The Board Of Trustees Of The Leland Stanford Junior University | Drug therapy for celiac sprue |
CA2502443A1 (en) | 2002-11-20 | 2004-06-03 | Pfizer Products Inc. | A method for preparing indan-1,3-dicarboxylic acid |
AU2003294473A1 (en) | 2002-11-20 | 2004-06-15 | The Board Of Trustees Of The Leland Stanford Junior University | Diagnostic method for celiac sprue |
MXPA05005517A (es) * | 2002-11-25 | 2005-07-25 | Pfizer Prod Inc | Procedimiento mejorado para la preparacion de indenos 1,3-disustituidos. |
RU2291862C2 (ru) * | 2003-01-15 | 2007-01-20 | Пфайзер Продактс Инк. | Способ получения арилконденсированных полициклических лактамов |
US20040224962A1 (en) * | 2003-05-09 | 2004-11-11 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
US20040224963A1 (en) * | 2003-05-09 | 2004-11-11 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
MXPA05012507A (es) * | 2003-05-20 | 2006-01-30 | Pfizer Prod Inc | Composiciones farmaceuticas de vareniclina. |
MXPA05013084A (es) * | 2003-06-04 | 2006-03-02 | Pfizer Prod Inc | Preparacion de quinoxalinas sustituidas a partir de la dianilina con 2,3-dihidroxi-1,4-dioxano. |
CA2533100A1 (en) * | 2003-07-21 | 2005-01-27 | Pfizer Products Inc. | Aryl fused azapolycyclic compounds |
DE602004023299D1 (de) | 2003-07-21 | 2009-11-05 | Pfizer Prod Inc | Nikotin abhängigkeit reduzierende heteroaryl kondensierte azapolycyclische verbindungen |
US20050043406A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
US20050043407A1 (en) * | 2003-08-22 | 2005-02-24 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of addiction in a mammal |
US7579313B2 (en) * | 2003-11-18 | 2009-08-25 | The Board Of Trustees Of The Leland Stanford Junior University | Transglutaminase inhibitors and methods of use thereof |
US7628985B2 (en) * | 2004-04-26 | 2009-12-08 | The Board Of Regents Of The Leland Stanford Junior University | Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis |
US7563864B2 (en) * | 2004-04-26 | 2009-07-21 | Celiac Sprue Research Foundation | Prolyl endopeptidase mediated destruction of T cell epitopes in whole gluten |
US7534426B2 (en) * | 2004-04-26 | 2009-05-19 | The Board Of Trustees Of The Leland Stanford Junior University | Glutenase enzyme assays |
WO2006006071A1 (en) * | 2004-07-07 | 2006-01-19 | Pfizer Products Inc. | Resolution of an aryl-fused azapolycyclic compound |
US7766018B2 (en) * | 2004-09-30 | 2010-08-03 | Smoke-Break, Inc. | Device and composition for reducing the incidence of tobacco smoking |
US20080275051A1 (en) * | 2005-02-24 | 2008-11-06 | Busch Frank R | Preparation of High Purity Substituted Quinoxalines |
US20060211649A1 (en) * | 2005-03-21 | 2006-09-21 | Eric Marchewitz | Use of cytisine for enhancing physical performance |
US20100048713A1 (en) * | 2006-01-06 | 2010-02-25 | Aarhus Universitet | Compounds acting on the serotonin transporter |
BRPI0709268A2 (pt) * | 2006-03-27 | 2011-06-28 | Pfizer Prod Inc | padrão de vareniclina e controles de impureza |
BRPI0710914A2 (pt) * | 2006-04-24 | 2011-09-27 | Pfizer Prod Inc | forma de dosagem e método para o tratamento de dependência, adição e supressão de nicotina, em particular para uso na terapia para parar de fumar |
WO2008028903A2 (en) | 2006-09-04 | 2008-03-13 | Neurosearch A/S | Pharmaceutical combinations of a nicotine receptor modulator and a cognitive enhancer |
WO2008060487A2 (en) * | 2006-11-09 | 2008-05-22 | Pfizer Products Inc. | Polymorphs of nicotinic intermediates |
CA2680590C (en) * | 2007-03-16 | 2017-10-17 | Jonathan David Gass | Combination enzyme therapy for digestion of dietary gluten |
WO2009034431A2 (en) | 2007-09-10 | 2009-03-19 | Pfizer Inc. | Controlled-release dosage forms for varenicline |
WO2009101185A2 (en) * | 2008-02-15 | 2009-08-20 | Medichem, S.A. | A NEW POLYMORPHIC FORM OF A PYRAZINO[2,3-h][3] BENZAZEPINE DERIVATIVE |
US20090215787A1 (en) * | 2008-02-22 | 2009-08-27 | Mai De Ltd. | Preparations of new polymorphic forms of varenicline tartrate |
WO2009146031A1 (en) | 2008-03-31 | 2009-12-03 | University Of South Florida | Methods of treating disease-induced ataxia and non-ataxic imbalance |
WO2009143347A2 (en) * | 2008-05-22 | 2009-11-26 | Teva Pharmaceutical Industries Ltd. | Varenicline tosylate, an intermediate in the preparation process of varenicline l-tartrate |
US20090318460A1 (en) * | 2008-05-26 | 2009-12-24 | Glenmark | Amorphous varenicline tartrate and process for the preparation thereof |
US20090318695A1 (en) * | 2008-06-19 | 2009-12-24 | Vinod Kumar Kansal | Processes for the preparation of varenicline and intermediates thereof |
WO2010005643A1 (en) * | 2008-07-10 | 2010-01-14 | Teva Pharmaceutical Industries Ltd. | Processes for purifying varenicline l-tartrate salt and preparing crystalline forms of varenicline l-tartrate salt |
US8314235B2 (en) * | 2008-09-01 | 2012-11-20 | Actavis Group Ptc Ehf | Process for preparing varenicline, varenicline intermediates, pharmaceutically acceptable salts thereof |
EP2204369A1 (en) | 2008-12-22 | 2010-07-07 | Medichem, S.A. | Process for preparing varenicline and intermediates for use therein |
SG173639A1 (en) * | 2009-02-11 | 2011-09-29 | Sunovion Pharmaceuticals Inc | Histamine h3 inverse agonists and antagonists and methods of use thereof |
US20120093887A1 (en) | 2009-06-10 | 2012-04-19 | Actavis Group Ptc Ehf | Amorphous varenicline tartrate co-precipitates |
WO2010151524A1 (en) | 2009-06-22 | 2010-12-29 | Teva Pharmaceutical Industries Ltd | Solid states forms of varenicline salts and processes for preparation thereof |
MX2012002827A (es) * | 2009-09-11 | 2012-04-10 | Sunovion Pharmaceuticals Inc | Agonistas inversos y antagonistas de histamina h3 y metodos para usar los mismos. |
EP2545054A1 (en) | 2010-03-09 | 2013-01-16 | Actavis Group Ptc Ehf | Highly pure varenicline or a pharmaceutically acceptable salt thereof substantially free of methylvarenicline impurity |
KR101109389B1 (ko) * | 2010-04-30 | 2012-01-30 | 삼성전기주식회사 | 인쇄회로기판 및 그 제조방법 |
WO2011140431A1 (en) | 2010-05-06 | 2011-11-10 | Teva Pharmaceutical Industries Ltd. | Varenicline salts and crystal forms thereof |
US20120004239A1 (en) | 2010-06-11 | 2012-01-05 | Medichem, S.A. | Process for Preparing Quinoxaline Derivatives |
JPWO2013002365A1 (ja) | 2011-06-30 | 2015-02-23 | 東レ株式会社 | 止痒剤 |
ITMI20111413A1 (it) | 2011-07-28 | 2013-01-29 | Dipharma Francis Srl | Procedimento per la preparazione di vareniclina |
ES2426838B1 (es) | 2012-04-20 | 2014-05-07 | Genetracer Biotech S.L | Método para predecir el éxito en el abandono del consumo de tabaco en respuesta a un tratamiento farmacológico |
ES2426517B1 (es) | 2012-04-20 | 2014-05-14 | Genetracer Biotech S.L | Método para predecir la seguridad de un tratamiento farmacológico |
CN103570502A (zh) * | 2012-07-18 | 2014-02-12 | 上海科胜药物研发有限公司 | 一种伐伦克林中间体的制备方法 |
US9636340B2 (en) | 2013-11-12 | 2017-05-02 | Ayyappan K. Rajasekaran | Kinase inhibitors |
CN103992272B (zh) * | 2014-06-09 | 2016-05-11 | 安徽省逸欣铭医药科技有限公司 | 一种盐酸喷他佐辛酯、其制备方法及其用途 |
KR20160126697A (ko) | 2015-04-24 | 2016-11-02 | 한미정밀화학주식회사 | 신규 결정형의 바레니클린 옥살산 염 수화물, 이의 제조방법, 및 이를 포함하는 약학 조성물 |
KR20160143407A (ko) | 2015-06-05 | 2016-12-14 | 한미정밀화학주식회사 | 신규한 바레니클린 뮤케이트 염, 이의 결정형 및 이의 제조방법 |
CN106674194B (zh) * | 2016-12-14 | 2019-03-05 | 山东省联合农药工业有限公司 | 一种结构新颖的烟碱类杀虫剂及其制备方法和用途 |
WO2018160043A1 (ko) | 2017-03-03 | 2018-09-07 | 주식회사 씨티씨바이오 | 바레니클린 또는 이의 약학적으로 허용가능한 염의 포접 복합체를 포함하는 구강 투여용 제제 |
KR102463733B1 (ko) | 2017-06-30 | 2022-11-04 | 한미약품 주식회사 | 함량 균일성 및 안정성이 향상된 바레니클린 옥살산염이 포함된 약제학적 조성물 |
WO2018154395A2 (en) | 2018-06-11 | 2018-08-30 | Alvogen Malta Operations (Row) Ltd | Controlled release pharmaceutical composition of varenicline |
KR20200034293A (ko) | 2018-09-21 | 2020-03-31 | 한미약품 주식회사 | 제어 방출용 바레니클린 제제 |
EP4142734A1 (en) | 2020-04-28 | 2023-03-08 | Oyster Point Pharma, Inc. | Local administration of nicotinic acetylcholine receptor agonists for the inhibition of coronavirus infections |
CN113956255A (zh) * | 2020-07-20 | 2022-01-21 | 威智医药有限公司 | 一种伐尼克兰中间体、伐尼克兰及其盐的制备方法 |
US11040983B1 (en) | 2020-08-14 | 2021-06-22 | Almatica Pharma Llc | Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof |
WO2022035434A1 (en) | 2020-08-14 | 2022-02-17 | Almatica Pharma Llc | Cocrystal of varenicline and oxalic acid, pharmaceutical composition thereof, and methods of use thereof |
WO2022147189A1 (en) * | 2020-12-30 | 2022-07-07 | Antares Pharma, Inc. | Varenicline prodrugs |
WO2022222019A1 (en) * | 2021-04-20 | 2022-10-27 | Suzhou Fude Zhaofeng Biochemical Technology Co., Ltd | Total synthesis of varenicline |
CN113277993B (zh) * | 2021-06-06 | 2023-07-21 | 湖南第一师范学院 | 一种Tafamidis及其衍生物的合成方法 |
WO2023275413A2 (en) | 2021-12-23 | 2023-01-05 | Medichem, S.A. | Solid pharmaceutical formulations of varenicline |
EP4241775A1 (en) | 2022-03-11 | 2023-09-13 | Par Pharmaceutical, Inc. | Tablet comprising varenicline and process of preparation thereof |
US11602537B2 (en) | 2022-03-11 | 2023-03-14 | Par Pharmaceutical, Inc. | Varenicline compound and process of manufacture thereof |
WO2024095172A1 (en) | 2022-11-04 | 2024-05-10 | Pfizer Inc. | Prodrugs of varenicline and compounds containing vulnerable amines |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3471503A (en) * | 1967-05-05 | 1969-10-07 | Mcneilab Inc | 1,2,3,5,6,7-hexahydro-4-phenethyl-2,6-methano-4h-4- benzazonin-12-ols |
CH644116A5 (de) * | 1980-08-21 | 1984-07-13 | Hoffmann La Roche | Imidazolderivate. |
EP0853621A1 (en) † | 1995-09-22 | 1998-07-22 | Novo Nordisk A/S | Novel substituted azacyclic or azabicyclic compounds |
US6605610B1 (en) * | 1997-12-31 | 2003-08-12 | Pfizer Inc | Aryl fused azapolycyclic compounds |
CN1324013C (zh) * | 1997-12-31 | 2007-07-04 | 辉瑞产品公司 | 芳基稠合氮杂多环化合物 |
WO1999042461A1 (en) * | 1998-02-23 | 1999-08-26 | Warner-Lambert Company | Substituted quinoxaline derivatives as interleukin-8 receptor antagonists |
EP0955301A3 (en) * | 1998-04-27 | 2001-04-18 | Pfizer Products Inc. | 7-aza-bicyclo[2.2.1]-heptane derivatives, their preparation and use according to their affinity for neuronal nicotinic acetylcholine receptors |
CA2330576A1 (en) * | 1998-04-29 | 1999-11-04 | Pfizer Products Inc. | Substituted benzazocines as nicotine-binding inhibitors |
ES2209825T3 (es) * | 1999-01-29 | 2004-07-01 | Abbott Laboratories | Derivados diazabiciclicos utiles como ligandos del receptor nicotinico de la acetilcolina. |
FR2788982B1 (fr) * | 1999-02-02 | 2002-08-02 | Synthelabo | Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique |
IL137937A0 (en) * | 1999-08-27 | 2001-10-31 | Pfizer Prod Inc | A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
DE60205742T2 (de) * | 2001-05-14 | 2006-05-11 | Pfizer Products Inc., Groton | Tartratsalze von 5,8,14-Triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaen |
CZ20032917A3 (cs) * | 2001-05-14 | 2004-07-14 | Pfizer Products Inc. | Citrátová sůl 5,8,14-triazatetracyklo(10,3,1,0 na druhou, na jedenáctou, 0 na čtvrtou, na devátou)-hexadeka-2(11),3,5,7,9-pentaenu |
ES2258652T3 (es) * | 2001-11-29 | 2006-09-01 | Pfizer Products Inc. | Sales de succinato de 5,8,14-triazatetraciclo(10.3.1.02,11.04,9)-hexadeca-2(11),3,5,7,9-pentaeno y composiciones farmaceuticas de los mismos. |
DE60218885T2 (de) * | 2001-11-30 | 2008-01-17 | Pfizer Products Inc., Groton | Orale pharmazeutische Arzneiformen bzw. Dosierungsformen von 5,8,14-Triazatetra-cyclo-(10.3.1.0 (2,11).0(4,9)-hexadeca-2(11),3,5,7,9-pentaen mit kontrollierter Freisetzung |
BR0214578A (pt) * | 2001-11-30 | 2004-11-03 | Pfizer Prod Inc | Compostos azopolicìclicos fundidos com arila |
CA2533100A1 (en) * | 2003-07-21 | 2005-01-27 | Pfizer Products Inc. | Aryl fused azapolycyclic compounds |
-
1998
- 1998-11-13 CN CNB988128195A patent/CN1324013C/zh not_active Expired - Lifetime
- 1998-11-13 SK SK971-2000A patent/SK286886B6/sk not_active IP Right Cessation
- 1998-11-13 CZ CZ20002438A patent/CZ301925B6/cs not_active IP Right Cessation
- 1998-11-13 JP JP2000527532A patent/JP3550359B2/ja not_active Expired - Lifetime
- 1998-11-13 EA EA200000592A patent/EA003190B1/ru not_active IP Right Cessation
- 1998-11-13 UA UA2000063807A patent/UA66825C2/uk unknown
- 1998-11-13 DK DK98950274T patent/DK1044189T4/en active
- 1998-11-13 US US09/402,010 patent/US6410550B1/en not_active Expired - Lifetime
- 1998-11-13 CA CA002316921A patent/CA2316921C/en not_active Expired - Lifetime
- 1998-11-13 AT AT98950274T patent/ATE386024T1/de active
- 1998-11-13 ME MEP-2008-702A patent/ME00459B/me unknown
- 1998-11-13 PL PL341824A patent/PL209404B1/pl unknown
- 1998-11-13 EP EP98950274.5A patent/EP1044189B2/en not_active Expired - Lifetime
- 1998-11-13 NZ NZ504482A patent/NZ504482A/xx not_active IP Right Cessation
- 1998-11-13 DE DE122008000038C patent/DE122008000038I1/de active Pending
- 1998-11-13 DE DE69839131.4T patent/DE69839131T3/de not_active Expired - Lifetime
- 1998-11-13 IL IL13672798A patent/IL136727A0/xx active Protection Beyond IP Right Term
- 1998-11-13 SI SI9830902T patent/SI1044189T2/sl unknown
- 1998-11-13 KR KR10-2000-7007379A patent/KR100408138B1/ko active IP Right Review Request
- 1998-11-13 PT PT98950274T patent/PT1044189E/pt unknown
- 1998-11-13 CN CNA2005100821428A patent/CN1715280A/zh active Pending
- 1998-11-13 AU AU96416/98A patent/AU753389C/en not_active Expired
- 1998-11-13 HU HU0100949A patent/HU230297B1/hu active Protection Beyond IP Right Term
- 1998-11-13 WO PCT/IB1998/001813 patent/WO1999035131A1/en active IP Right Grant
- 1998-11-13 BR BRPI9814592-4A patent/BR9814592B1/pt not_active IP Right Cessation
- 1998-11-13 RS YUP-403/00A patent/RS50069B/sr unknown
- 1998-11-13 SG SG200203917A patent/SG102686A1/en unknown
- 1998-11-13 TR TR2000/01840T patent/TR200001840T2/xx unknown
- 1998-11-13 EP EP05106853A patent/EP1659114A3/en not_active Withdrawn
- 1998-11-13 ES ES98950274.5T patent/ES2301210T5/es not_active Expired - Lifetime
- 1998-11-13 BR BRPI9816186-5A patent/BR9816186B1/pt not_active IP Right Cessation
- 1998-11-19 HN HN1998000177A patent/HN1998000177A/es unknown
- 1998-11-30 PA PA19988463901A patent/PA8463901A1/es unknown
- 1998-11-30 CO CO98070723A patent/CO4810373A1/es unknown
- 1998-12-15 GT GT199800200A patent/GT199800200A/es unknown
- 1998-12-15 GT GT199800200AK patent/GT199800200AA/es unknown
- 1998-12-17 AP APAP/P/1998/001422A patent/AP1170A/en active
- 1998-12-28 PE PE1998001286A patent/PE20000053A1/es not_active IP Right Cessation
- 1998-12-28 TW TW087121748A patent/TW513412B/zh not_active IP Right Cessation
- 1998-12-28 EG EG161298A patent/EG23816A/xx active
- 1998-12-29 AR ARP980106715A patent/AR017967A1/es active IP Right Grant
- 1998-12-29 ZA ZA9811911A patent/ZA9811911B/xx unknown
- 1998-12-30 MY MYPI98005949A patent/MY118163A/en unknown
- 1998-12-30 DZ DZ980307A patent/DZ2697A1/xx active
- 1998-12-30 MA MA25409A patent/MA26589A1/fr unknown
- 1998-12-30 TN TNTNSN98237A patent/TNSN98237A1/fr unknown
-
1999
- 1999-02-28 SA SA99191123A patent/SA99191123B1/ar unknown
-
2000
- 2000-05-26 IS IS5514A patent/IS5514A/is unknown
- 2000-06-12 IL IL136727A patent/IL136727A/en active Protection Beyond IP Right Term
- 2000-06-16 OA OA1200000175A patent/OA11428A/en unknown
- 2000-06-27 BG BG104561A patent/BG65058B1/bg unknown
- 2000-06-30 HR HR20000445A patent/HRP20000445B1/xx not_active IP Right Cessation
- 2000-06-30 NO NO20003422A patent/NO319115B1/no not_active IP Right Cessation
-
2001
- 2001-04-09 HK HK01102476A patent/HK1031878A1/xx not_active IP Right Cessation
-
2002
- 2002-02-13 US US10/075,843 patent/US6887884B2/en not_active Expired - Fee Related
- 2002-02-14 US US10/075,348 patent/US20020072524A1/en not_active Abandoned
- 2002-04-22 US US10/127,267 patent/US6951938B2/en not_active Expired - Lifetime
- 2002-04-23 US US10/131,278 patent/US6897310B2/en not_active Expired - Lifetime
-
2005
- 2005-06-07 HR HR20050506A patent/HRP20050506A2/hr not_active Application Discontinuation
-
2006
- 2006-11-17 NO NO2006016C patent/NO2006016I1/no not_active IP Right Cessation
-
2007
- 2007-07-17 US US11/778,890 patent/US20070275973A1/en not_active Abandoned
-
2008
- 2008-04-14 CY CY20081100397T patent/CY1107391T1/el unknown
- 2008-05-21 LU LU91442C patent/LU91442I2/fr unknown
- 2008-06-05 NL NL300355C patent/NL300355I2/nl unknown
- 2008-07-03 CY CY200800013C patent/CY2008013I2/el unknown
- 2008-07-21 FR FR08C0039C patent/FR08C0039I2/fr active Active
-
2016
- 2016-04-27 HU HUS1600018C patent/HUS1600018I1/hu unknown
Non-Patent Citations (1)
Title |
---|
Journal of Medicinal Chemistry, Vol. 22(4) : 455-457 (1979) * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101724301B1 (ko) | 2016-11-22 | 2017-04-10 | 주식회사 한서켐 | 바레니클린 살리실산염의 i형 결정 및 그 제조방법 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100408138B1 (ko) | 아릴 융합된 아자폴리사이클릭 화합물 | |
DE60120366T2 (de) | Aryl-kondensierte azopolycyclische Verbindungen | |
KR100551183B1 (ko) | 1,3-치환 인덴 및 아릴-융합 아자폴리시클릭 화합물의제조 방법 | |
AU2002234836A1 (en) | Process for the preparation of 1,3-substituted indenes and aryl-fused azapolycyclic compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
AMND | Amendment | ||
E902 | Notification of reason for refusal | ||
AMND | Amendment | ||
E601 | Decision to refuse application | ||
AMND | Amendment | ||
J201 | Request for trial against refusal decision | ||
B701 | Decision to grant | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121030 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20131030 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20141030 Year of fee payment: 12 |
|
J204 | Request for invalidation trial [patent] | ||
J204 | Request for invalidation trial [patent] | ||
J121 | Written withdrawal of request for trial | ||
FPAY | Annual fee payment |
Payment date: 20150930 Year of fee payment: 13 |
|
J121 | Written withdrawal of request for trial | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20150424 Effective date: 20151126 |
|
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
FPAY | Annual fee payment |
Payment date: 20161028 Year of fee payment: 14 |
|
J121 | Written withdrawal of request for trial | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J206 | Request for trial to confirm the scope of a patent right | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J121 | Written withdrawal of request for trial | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2017100001942; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170623 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100001826; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170615 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100002368; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170726 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100001823; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170615 Effective date: 20180411 Free format text: TRIAL NUMBER: 2016100002953; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160923 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100001943; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170623 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100001939; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170623 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100001938; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170623 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100001937; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170623 Effective date: 20180411 Free format text: TRIAL NUMBER: 2016100002944; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160923 Effective date: 20180411 Free format text: TRIAL NUMBER: 2016100002936; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160923 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100001940; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170623 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100001945; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170623 Effective date: 20180411 Free format text: TRIAL NUMBER: 2016100002948; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160923 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100001941; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170623 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100001322; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170426 Effective date: 20180411 Free format text: TRIAL NUMBER: 2016100002918; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160923 Effective date: 20180411 Free format text: TRIAL NUMBER: 2016100002956; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160923 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100001944; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170623 Effective date: 20180411 Free format text: TRIAL NUMBER: 2016100002949; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20160923 Effective date: 20180411 Free format text: TRIAL NUMBER: 2017100001396; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20170504 Effective date: 20180411 |
|
J121 | Written withdrawal of request for trial | ||
J122 | Written withdrawal of action (patent court) | ||
FPAY | Annual fee payment |
Payment date: 20180928 Year of fee payment: 16 |
|
J204 | Request for invalidation trial [patent] | ||
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2019100000651; TRIAL DECISION FOR INVALIDATION REQUESTED 20190222 Effective date: 20190524 Free format text: TRIAL NUMBER: 2019100000653; TRIAL DECISION FOR INVALIDATION OF EXTENSION OF TERM REQUESTED 20190222 Effective date: 20190524 |
|
J202 | Request for trial for correction [limitation] | ||
G170 | Re-publication after modification of scope of protection [patent] | ||
FPAY | Annual fee payment |
Payment date: 20190924 Year of fee payment: 17 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2019105000051; TRIAL DECISION FOR CORRECTION REQUESTED 20190527 Effective date: 20191007 |
|
J302 | Written judgement (patent court) |
Free format text: TRIAL NUMBER: 2018200004041; JUDGMENT (PATENT COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20180510 Effective date: 20191220 Free format text: TRIAL NUMBER: 2018200004058; JUDGMENT (PATENT COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20180510 Effective date: 20191220 |
|
J302 | Written judgement (patent court) |
Free format text: TRIAL NUMBER: 2019200004727; JUDGMENT (PATENT COURT) FOR INVALIDATION REQUESTED 20190621 Effective date: 20191220 |
|
J302 | Written judgement (patent court) |
Free format text: TRIAL NUMBER: 2018200004089; JUDGMENT (PATENT COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20180510 Effective date: 20191220 Free format text: TRIAL NUMBER: 2018200004102; JUDGMENT (PATENT COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20180510 Effective date: 20191220 Free format text: TRIAL NUMBER: 2018200004119; JUDGMENT (PATENT COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20180510 Effective date: 20191220 Free format text: TRIAL NUMBER: 2018200004065; JUDGMENT (PATENT COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20180510 Effective date: 20191220 Free format text: TRIAL NUMBER: 2018200004096; JUDGMENT (PATENT COURT) FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20180510 Effective date: 20191220 |
|
J301 | Trial decision |
Free format text: TRIAL NUMBER: 2020130000025; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000028; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000011; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200113 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000017; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000022; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000019; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000021; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000016; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000018; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000015; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000024; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000027; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000010; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200113 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000020; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000023; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 Free format text: TRIAL NUMBER: 2020130000026; TRIAL DECISION FOR CONFIRMATION OF THE SCOPE OF RIGHT_DEFENSIVE REQUESTED 20200129 Effective date: 20200211 |